Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019
Executive Summary
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
You may also be interested in...
Jumping Before They Were Pushed – Kiadis And Aradigm Withdraw EU Filings
Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP.
Xeris Joins Lilly On Market With Approval Of Easier-To-Use Glucagon
Xeris’s Gvoke gets FDA approval, joining Lilly’s Baqsimi as products to treat emergency episodes of hypoglycemia with an easier-to-use kit. Xeris will launch its prefilled syringe in Q4 and an auto-injector in 2020.
IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
Need a specific report? 1000+ reports available
Buy Reports